Tesamorelin / Ipamorelin

GH Optimization Blend

A synergistic GHRH + GHRP combination for enhanced GH pulsatility and visceral fat reduction.

100% 50% · t½ Time → Serum level
Molecular Weight
—
Half-Life
Varies
Typical Dose
0.75 mg to 2.25 mg
Cycle Length
8–16 weeks

Description

This combination pairs Tesamorelin (GHRH analog) with Ipamorelin (GHRP) for synergistic GH release. Tesamorelin provides the GHRH stimulus while Ipamorelin amplifies the GH pulse through GHS-R1a, resulting in greater GH secretion than either alone.

Key Characteristics

Molecular WeightNot specified
Half-LifeVaries
Administration RoutesSubcutaneous injection
Typical Dose0.75 mg to 2.25 mg
FrequencyDaily (bedtime preferred)
Cycle Length8–16 weeks

Investigated Benefits

  • Synergistic GH release
  • Improved body composition
  • Better sleep quality
  • Visceral fat reduction
  • Enhanced recovery

* Benefits based on preclinical/animal research unless otherwise noted.